Remus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Remus Pharmaceuticals has a total shareholder equity of ₹1.0B and total debt of ₹115.5M, which brings its debt-to-equity ratio to 11.1%. Its total assets and total liabilities are ₹2.6B and ₹1.5B respectively. Remus Pharmaceuticals's EBIT is ₹269.1M making its interest coverage ratio 55.6. It has cash and short-term investments of ₹293.5M.
Key information
11.1%
Debt to equity ratio
₹115.47m
Debt
| Interest coverage ratio | 55.6x |
| Cash | ₹293.45m |
| Equity | ₹1.04b |
| Total liabilities | ₹1.53b |
| Total assets | ₹2.57b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: REMUS's short term assets (₹2.1B) exceed its short term liabilities (₹1.5B).
Long Term Liabilities: REMUS's short term assets (₹2.1B) exceed its long term liabilities (₹34.6M).
Debt to Equity History and Analysis
Debt Level: REMUS has more cash than its total debt.
Reducing Debt: Insufficient data to determine if REMUS's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: REMUS's debt is well covered by operating cash flow (31.2%).
Interest Coverage: REMUS's interest payments on its debt are well covered by EBIT (55.6x coverage).